브라이어셀 테라퓨틱스(BCTX)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $3.44 (+0.00%), 시가총액 $0.03B, 52주 범위 $0.63 ~ $13.79.
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp., has a collaboration with
브라이어셀 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.
브라이어셀 테라퓨틱스의 현재 주가는 $3.44 (+0.00%)입니다. BlackQuant에서 실시간 시세와 차트를 확인할 수 있습니다.
브라이어셀 테라퓨틱스의 시가총액은 약 $0.03B입니다.
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunothe